Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (#A4 TAU#)

The A4 study is to designed to test the hypothesis that solanezumab, will slow decline on a cognitive composite measure designed to be sensitive to early decline in the preclinical stages of AD. The A4-Tau study will evaluate whether treatment with an anti-amyloid therapy will slow increase in tau deposition over time, as measure by sequential PET scans of 18F-AV-1451, in subjects with preclinical AD in the A4 trial.